Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference

CAMBRIDGE, Mass., March 1, 2023 /<u>PRNewswire</u>/ -- <u>Nuvalent, Inc.</u> (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023, at 9:10 a.m. ET in Boston.

A live webcast will be available in the Investors section of the company's website at<u>www.nuvalent.com</u>, and archived for 30 days following the presentation.

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), a program in HER2 Exon 20 insertion-positive cancers, and multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at <u>www.nuvalent.com</u>. Follow us on Twitter (<u>@nuvalent</u>) and <u>LinkedIn</u>.

SOURCE Nuvalent, Inc.

Investor Contact: Chelcie Lister THRUST Strategic Communications <u>chelcie@thrustsc.com</u>

Media Contact: Amanda Sellers Verge Scientific Communications asellers@vergescientific.com

https://investors.nuvalent.com/2023-03-01-Nuvalent-to-Participate-in-the-43rd-Annual-Cowen-Healthcare-Conference